临床试验/NCT04756960

NCT04756960已完成1 期

Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 Following a Single Inhaled Dose Co-administered With an Intravenous Radiolabelled Microtracer Dose in Healthy Volunteers

Chiesi Farmaceutici S.p.A.1 个研究点分布在 1 个国家目标入组 8 人开始时间: 2021年3月10日最近更新: 2024年3月18日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方: Chiesi Farmaceutici S.p.A.
入组人数: 8
试验地点: 1
主要终点: PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The objective of the study is to evaluate the bioavailability of CHF6001 after inhaled administration, to characterize the mass balance and route of elimination of CHF6001 along with its relevant metabolites, in healthy male subjects.

详细描述

This clinical trial is a single centre Phase I study, with a single dose, non-randomized, open-label, uncontrolled design. A total of 8 healthy male subjects were included in the study.

The aim was to assess the absolute bioavailability, the mass balance, and routes of elimination of CHF6001 (Tanimilast) in healthy male subjects, using [14^C]-radiolabelled drug substance, administered as an intravenous (iv) infusion concomitantly with an inhaled (inh) non-radiolabelled dose of CHF6001.

Standard safety assessments were conducted during the study, including safety blood and urine laboratory tests, vital signs, physical examinations, ECGs, and assessment of any adverse events (AE). Blood, urine, and feces samples were collected for pharmacokinetic (PK) analyses.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Other
盲法: None

入排标准

年龄范围: 30 Years 至 55 Years（Adult）
性别: Male
接受健康志愿者: 是

入选标准

•Subject's written informed consent obtained prior to any study-related procedure;
•Able to understand the study procedures, the risks involved and ability to be trained to use correctly the inhalers and to generate sufficient Peak Inspiratory Flow (PIF), using the In-Check device and Placebo inhaler;
•Male subjects aged 30 to 55 years inclusive;
•Body mass index (BMI) within the range of 18 to 35 kg/m^2 inclusive;
•Non- or ex-smoker who smoked < 5 pack years and who stopped smoking > 1 year prior to screening;
•Good physical and mental status;
•Vital signs at screening within limits;
•12-lead digitised Electrocardiogram (12-lead ECG) in triplicate considered as normal;
•Lung function measurements within normal limits at screening;
•Regular bowel movements at screening;
•Males with non-pregnant Women of Childbearing Potential (WOCBP) partners: they and/or their partner of childbearing potential must be willing to use a highly effective birth control method in addition to the male condom from the signature of the informed consent and until 90 days after the follow-up visit. Males with pregnant WOCBP partner: they must be willing to use male contraception (condom) from the signature of the informed consent and until 90 days after the follow-up visit.

排除标准

•Participation in another clinical trial with an investigational drug in the 3 months or 5 half-lives of that investigational drug (whichever is longer) preceding the administration of the study drug;
•Clinically relevant and uncontrolled respiratory, cardiac, hepatic (including Gilbert syndrome), gastrointestinal, renal, endocrine, metabolic, neurologic, or psychiatric disorder;
•Clinically relevant abnormal laboratory values;
•Subjects with history of breathing problems;
•Positive to Human Immunodeficiency Virus 1/Human Immunodeficiency Virus 2 (HIV1/HIV2) serology at screening;
•Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C at screening;
•Blood donation or blood loss (equal or more than 450 mL) less than 2 months prior screening or prior to treatment;
•Positive urine test for cotinine;
•Documented history of alcohol abuse within 12 months prior to screening or a positive alcohol breath test;
•Documented history of drug abuse within 12 months prior to screening or a positive urine drug screen;
•Intake of non-permitted concomitant medications in the predefined period;
•Presence of any current infection, or previous infection that resolved less than 7 days prior to screening or before treatment;
•Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation used in the trial;
•Unsuitable veins for repeated venipuncture;
•Heavy caffeine drinker;
•Abnormal haemoglobin level at screening;
•Subjects using e-cigarettes within 6 months prior to screening;
•Subjects been involved in a study involving a 14^C-labeled drug within the 12 months prior to enrollment;
•Subjects with exposure to significant diagnostic or therapeutic radiation or current employment in a job requiring radiation exposure monitoring within 12 months prior to Day-1;
•Documented coronavirus disease 2019 (COVID-19) diagnosis within the last 8 weeks or which has not resolved within 14 days prior to screening and before treatment.

研究组 & 干预措施

CHF6001

Experimental

single dose of CHF6001 dry-powder inhaler (DPI) co-administered with an intravenous microdose of [14^C]-labelled CHF6001

干预措施: CHF6001 (Drug)

结局指标

主要结局

PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] Total

时间窗: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints relative to the start of the IV infusion: 5, 10, 15 [end of infusion], 20, 25, 30, 45, 60 min, 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216, and 240 hours.

Terminal half-life t(1/2_iv) for \[14\^C\] total and CHF6001. t1/2_iv=Terminal half-life, after intravenous (iv) infusion administration

PK Parameter -- Clearance (CL_iv) -- Plasma -- [14^C] CHF6001

Systemic plasma clearance for \[14\^C\] CHF6001.

PK Parameter -- C(max_inh) -- Plasma -- CHF6001

时间窗: Pre-dose (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours.

C(max_inh) for CHF6001 in plasma. C(max_inh)=Peak plasma concentration after inhalation of CHF6001

PK Parameter -- AUC(0-t)_inh -- Plasma -- CHF6001

时间窗: At baseline (pre-dose) (within 60 min from inhaled dosing) and at the following timepoints post inhaled dose: 15, 30, 60, 90 min, 2, 3.75, 5.75, 7.75, 9.75, 11.75, 13.75, 25.75, 49.75, 73.75, 97.75, 121.75, 145.75, 169.75, 193.75, 217.75, and 241.75 hours

AUC(0-t)_inh for CHF6001 in plasma. AUC(0-t)_inh=Area Under the curve, from 0 to the last quantifiable concentration after inhalation of CHF6001

PK Parameter -- t(max_inh) -- Plasma -- CHF6001

t(max_inh) for CHF6001 in plasma. t(max_inh)=Time to reach the Cmax after inhalation of CHF6001

PK Parameter -- AUC(0-∞_inh) -- Plasma -- CHF6001

AUC(0-∞_inh) for CHF6001 in plasma. AUC(0-∞_inh)=Area under curve extrapolated to infinity after inhalation of CHF6001

PK Parameter -- t(1/2_inh) -- Plasma -- CHF6001

t(1/2_inh) for CHF6001 in plasma. t(1/2_inh)=Terminal half-life, after inhalation of CHF6001

PK Parameter -- Absolute Inhaled Bioavailability (F_inh) -- Plasma -- CHF6001

Absolute inhaled bioavailability for CHF6001. F_inh=Inhaled absolute bioavailability based on AUC(0-∞) after inhalation of CHF6001 F_inh=(AUC(0-∞)_inh x Dose_iv)/ (AUC(0-∞)_iv x Dose_inh).

PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C] Total

时间窗: Baseline (pre dose, -12-0h) and relative to the start of the IV infusion at: 0-4h, 4-8h, 8-12h, 12-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216-240h.

Urine excreted fraction for cumulative \[14\^C\] total.

PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine -- [14^C]-CHF6001

Urine excreted fraction for cumulative \[14\^C\]-CHF6001. Measurements in urine were performed. All measured values were below the limit of quantification of the bioanalytical method.

PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total

AUC(0-t_iv) for \[14\^C\] total in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration.

PK Parameter -- C(max_iv) -- Plasma -- [14^C] Total

C(max_iv) for \[14\^C\] total in plasma. C(max_iv)=Peak plasma concentration after intravenous (iv) infusion administration

PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] CHF6001

AUC(0-t_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-t_iv)=Area Under the curve, from 0 to the last quantifiable concentration, after intravenous (iv) infusion administration

PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] CHF6001

Area under curve extrapolated to infinity (AUC0-∞_iv) for \[14\^C\] CHF6001 in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

PK Parameter -- Volume of Distribution During the Terminal Phase (Vz_iv) -- Plasma -- [14^C] CHF6001

Volume of distribution during the terminal phase (Vz_iv) of \[14\^C\] CHF6001 in plasma. Vz_iv=Volume of distribution during the terminal phase, after intravenous (iv) infusion administration

PK Parameter -- t(max_iv) -- Plasma -- [14^C] Total

t(max_iv) for \[14\^C\] total. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

PK Parameter -- AUC(0-∞_iv) -- Plasma -- [14^C] Total

Area under curve extrapolated to infinity (AUC(0-∞_iv) for \[14\^C\] total in plasma. AUC(0-∞_iv)=Area under curve extrapolated to infinity, after intravenous (iv) infusion administration

PK Parameter -- (Blood to Plasma Ratio) -- Blood, Plasma -- [14^C] Total

时间窗: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

Blood to plasma ratio for \[14\^C\] total.

PK Parameter -- C(max_iv) -- Plasma -- [14^C] CHF6001

C(max_iv) for \[14\^C\] CHF6001 in plasma. C(max_iv)=Peak plasma concentration, after intravenous (iv) infusion administration

PK Parameter -- t(max_iv) -- Plasma -- [14^C] CHF6001

t(max_iv) for \[14\^C\] CHF6001. t(max_iv)=Time to reach the Cmax, after intravenous (iv) infusion administration

PK Parameter -- t(1/2_iv) -- Plasma -- [14^C] CHF6001

Terminal half-life t(1/2_iv) for \[14\^C\] CHF6001 in plasma. t(1/2_iv)=Terminal half-life, after intravenous (iv) infusion administration

PK Parameter -- Vdss_iv -- Plasma -- [14^C] CHF6001

Vdss_iv=Volume of distribution is calculated at steady-state for \[14\^C\] CHF6001 in plasma, after intravenous (iv) infusion administration.

PK Parameter -- Blood to Plasma Ratio -- Blood, Plasma -- [14^C] CHF6001

时间窗: Pre-dose (within 60 min from inhaled dosing) and at 20 min after the start of IV infusion.

Blood to plasma ratio for \[14\^C\] CHF6001.

PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C] Total

时间窗: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

Fecal excreted fraction for cumulative \[14\^C\] total.

PK Parameter -- Cumulative Excreted Fraction (in %) -- Fecal -- [14^C]-CHF6001

时间窗: Baseline (pre dose, Day -1) and relative to the start of the IV infusion at: 0-24h, 24-48h, 48-72h, 72-96h, 96-120h, 120-144h, 144-168h, 168-192h, 192-216h, and 216 -240h.

Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C] Total

时间窗: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

Urine and fecal excreted fraction for cumulative \[14\^C\] total.

PK Parameter -- Cumulative Excreted Fraction (in %) -- Urine and Fecal -- [14^C]-CHF6001

时间窗: Over 240 h after administration; please see timepoints for outcome #22 (urine) and #24 (fecal).

Urine and Fecal excreted fraction for cumulative \[14\^C\]-CHF6001.

次要结局

未报告次要终点

研究者

发起方

Chiesi Farmaceutici S.p.A.

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

已完成

1 期

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy VolunteersAsthma

NCT02359292Chiesi Farmaceutici S.p.A.50

已完成

1 期

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the VeinHealthy

NCT05075772Boehringer Ingelheim28

已完成

1 期

Mesalamine 4 gm/60 mL Rectal EnemaHealthy

NCT00840203Teva Pharmaceuticals USA72

撤回

1 期

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male SubjectsHealthy

NCT02175238Boehringer Ingelheim

已完成

早期 1 期

Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose StudyGastroesophageal Reflux Disease

NCT02072447Seoul National University Hospital8